Five miRNAs Considered as Molecular Targets for Predicting Esophageal Cancer

Jia-ying Zhao1, Fei Wang1, Yi Li1

  • 1Department of Thoracic Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China (mainland).

Abstract

Insights

Researchers identified differentially expressed microRNAs (DEMs) in esophageal cancer (EC). Five specific miRNAs show potential for diagnosing and preventing EC, offering new therapeutic targets.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genomics

Background:

  • Esophageal cancer (EC) is an aggressive malignancy with limited traditional therapy effectiveness.
  • Novel therapeutic strategies are crucial for improving EC treatment outcomes.
  • Identifying key molecular players in EC pathogenesis is essential for developing new treatments.

Purpose of the Study:

  • To screen for differentially expressed microRNAs (DEMs) in esophageal cancer.
  • To investigate the pathogenesis of EC by analyzing target genes of DEMs.
  • To explore the functional pathways associated with these target genes.

Main Methods:

  • High-throughput miRNA sequencing data from The Cancer Genome Atlas (TCGA) were analyzed.
  • Differentially expressed miRNAs (DEMs) were identified and subjected to principal component analysis (PCA).
  • Target genes were predicted using TargetScan, followed by enrichment and pathway analysis (DAVID, KEGG), and survival analysis.

Main Results:

  • A total of 140 DEMs were identified, with 113 upregulated and 27 downregulated.
  • Specific upregulated miRNAs include hsa-mir-153-2, hsa-mir-92a-1, and hsa-mir-182.
  • Five miRNAs (hsa-mir-103-1, hsa-mir-18a, hsa-mir-324, hsa-mir-369, hsa-mir-320b-2) significantly correlated with patient survival.

Conclusions:

  • Key molecular targets like p53 may hold significant clinical value for EC treatment.
  • miRNA target genes are implicated in protein phosphorylation, suggesting a novel therapeutic avenue.
  • Further research into the role of these target genes in protein phosphorylation is recommended for EC therapy development.